9 Meters Biopharma (NMTR) Competitors Add Compare Share Share Competitors Stock AnalysisChartCompetitorsInsider TradesSEC FilingsTrendsBuy This Stock NMTR vs. EVAX, DRMA, BDRX, ARTL, SHPH, GLTO, RDHL, QLGN, PWUP, and ENVBShould you be buying 9 Meters Biopharma stock or one of its competitors? The main competitors of 9 Meters Biopharma include Evaxion A/S (EVAX), Dermata Therapeutics (DRMA), Biodexa Pharmaceuticals (BDRX), Artelo Biosciences (ARTL), Shuttle Pharmaceuticals (SHPH), Galecto (GLTO), Redhill Biopharma (RDHL), Qualigen Therapeutics (QLGN), PowerUp Acquisition (PWUP), and Enveric Biosciences (ENVB). These companies are all part of the "pharmaceutical products" industry. 9 Meters Biopharma vs. Its Competitors Evaxion A/S Dermata Therapeutics Biodexa Pharmaceuticals Artelo Biosciences Shuttle Pharmaceuticals Galecto Redhill Biopharma Qualigen Therapeutics PowerUp Acquisition Enveric Biosciences Evaxion A/S (NASDAQ:EVAX) and 9 Meters Biopharma (NASDAQ:NMTR) are both small-cap medical companies, but which is the better investment? We will compare the two businesses based on the strength of their earnings, dividends, media sentiment, valuation, profitability, institutional ownership, risk and analyst recommendations. Which has more volatility and risk, EVAX or NMTR? Evaxion A/S has a beta of 0.14, indicating that its stock price is 86% less volatile than the S&P 500. Comparatively, 9 Meters Biopharma has a beta of 1.36, indicating that its stock price is 36% more volatile than the S&P 500. Does the media refer more to EVAX or NMTR? In the previous week, Evaxion A/S had 1 more articles in the media than 9 Meters Biopharma. MarketBeat recorded 1 mentions for Evaxion A/S and 0 mentions for 9 Meters Biopharma. Evaxion A/S's average media sentiment score of 0.75 beat 9 Meters Biopharma's score of 0.00 indicating that Evaxion A/S is being referred to more favorably in the media. Company Overall Sentiment Evaxion A/S Positive 9 Meters Biopharma Neutral Which has better valuation & earnings, EVAX or NMTR? Evaxion A/S has higher revenue and earnings than 9 Meters Biopharma. Evaxion A/S is trading at a lower price-to-earnings ratio than 9 Meters Biopharma, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioEvaxion A/S$3.34M1.29-$10.57M-$1.32-2.339 Meters BiopharmaN/AN/A-$43.77M-$3.46N/A Do analysts prefer EVAX or NMTR? Evaxion A/S presently has a consensus price target of $10.00, suggesting a potential upside of 225.73%. Given Evaxion A/S's stronger consensus rating and higher probable upside, analysts clearly believe Evaxion A/S is more favorable than 9 Meters Biopharma.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Evaxion A/S 0 Sell rating(s) 0 Hold rating(s) 2 Buy rating(s) 0 Strong Buy rating(s) 3.009 Meters Biopharma 0 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 0.00 Is EVAX or NMTR more profitable? 9 Meters Biopharma has a net margin of 0.00% compared to Evaxion A/S's net margin of -316.03%. Evaxion A/S's return on equity of -319.52% beat 9 Meters Biopharma's return on equity.Company Net Margins Return on Equity Return on Assets Evaxion A/S-316.03% -319.52% -63.56% 9 Meters Biopharma N/A -584.97%-159.45% Do institutionals and insiders hold more shares of EVAX or NMTR? 11.0% of Evaxion A/S shares are owned by institutional investors. Comparatively, 22.3% of 9 Meters Biopharma shares are owned by institutional investors. 41.6% of Evaxion A/S shares are owned by company insiders. Comparatively, 2.4% of 9 Meters Biopharma shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock is poised for long-term growth. SummaryEvaxion A/S beats 9 Meters Biopharma on 11 of the 15 factors compared between the two stocks. Get 9 Meters Biopharma News Delivered to You Automatically Sign up to receive the latest news and ratings for NMTR and its competitors with MarketBeat's FREE daily newsletter. Subscribe Now View SMS TermsBy entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding NMTR and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart NMTR vs. The Competition Export to ExcelMetric9 Meters BiopharmaBiotechnology IndustryMedical SectorNASDAQ ExchangeMarket Cap$1.04M$237.75M$5.78B$10.27BDividend YieldN/A3.78%5.74%4.64%P/E Ratio0.0033.9276.5826.99Price / SalesN/A4,870.40512.47164.74Price / CashN/A13.1937.1760.63Price / BookN/A131.7313.586.37Net Income-$43.77M-$90.99M$3.29B$271.62M 9 Meters Biopharma Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)NMTR9 Meters BiopharmaN/AN/AN/AN/A$1.04MN/A0.0020EVAXEvaxion A/S2.3944 of 5 stars$2.94+0.7%$10.00+240.1%-80.6%$4.13M$3.18M-2.2360Positive NewsGap DownDRMADermata Therapeutics1.9583 of 5 stars$5.91+8.8%$10.00+69.2%-74.5%$4.02MN/A-0.368Gap UpBDRXBiodexa Pharmaceuticals0.6031 of 5 stars$6.26+3.8%N/AN/A$3.88MN/A0.0020Gap UpARTLArtelo Biosciences2.959 of 5 stars$5.46+4.0%$24.00+339.6%-15.8%$3.84MN/A-0.295Short Interest ↓SHPHShuttle Pharmaceuticals0.8794 of 5 stars$3.58+3.2%N/A-89.3%$3.83MN/A-0.865News CoveragePositive NewsShort Interest ↓GLTOGalecto3.4889 of 5 stars$2.75-2.8%$10.00+263.6%-79.1%$3.64MN/A-0.2140RDHLRedhill BiopharmaN/A$1.53+2.3%N/A-82.6%$3.53M$8.04M0.00210Short Interest ↑QLGNQualigen TherapeuticsN/A$2.00-1.5%N/A-67.4%$3.39MN/A0.0050PWUPPowerUp AcquisitionN/A$0.41-3.1%N/A-96.2%$3.20MN/A0.00N/AGap UpHigh Trading VolumeENVBEnveric Biosciences2.0583 of 5 stars$0.92-2.7%$10.00+992.9%-91.4%$2.97MN/A-0.0220Gap UpHigh Trading Volume Related Companies and Tools Related Companies EVAX Alternatives DRMA Alternatives BDRX Alternatives ARTL Alternatives SHPH Alternatives GLTO Alternatives RDHL Alternatives QLGN Alternatives PWUP Alternatives ENVB Alternatives Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:NMTR) was last updated on 9/19/2025 by MarketBeat.com Staff From Our PartnersTrump’s national nightmare is herePorter Stansberry and Jeff Brown say a new U.S. national emergency is already underway — and it could trigger ...Porter & Company | SponsoredHe Called Nvidia at $1.10. Now, He Says THIS Stock Will…The original Magnificent Seven returned 16,894%—turning $7K into $1.18 million. Now, the man who called Nvi...The Oxford Club | SponsoredOut of 18,347 Cryptocurrencies... This is the ONLY OneThe Single Most Undervalued DeFi Protocol You've Never Heard Of If there's one cryptocurrency you should b...Crypto 101 Media | SponsoredTrump’s Plan May Undo 1933’s Biggest Financial InjusticeTrump's Reset Can Give Birth To America's Greatest Era Yet A 90-Year cycle may end soon, creating real weal...American Hartford Gold | SponsoredStunning new initiative unfolding in the White House?what I just learned about what’s unfolding in the White House is truly stunning… And you need to see it for...Paradigm Press | SponsoredA New Way to Double Your Retirement Income?Bloomberg reports that a new class of investments is “entering a golden era,” with yields fueling a retail boo...Investors Alley | SponsoredINVESTOR ALERT: Tiny “$3 AI Wonder Stock” on the Verge of Blasting OffRight now, we’re witnessing a monumental shift in the world.Traders Agency | SponsoredStrange crypto pattern discovered by 40-person research teamSomething unusual is happening inside a 40-person crypto research firm. They're helping 8,000+ ordinary peo...Crypto Swap Profits | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding 9 Meters Biopharma, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share 9 Meters Biopharma With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Free NMTR Stock Alerts